On Wednesday, DexCom, Inc. (NASDAQ:DXCM) maintained its Outperform rating and a $145.00 price target from Oppenheimer, following the U.S. Food and Drug Administration's (FDA) approval of its Stelo Continuous Glucose Monitoring (CGM) system for Type 2 diabetes patients not using insulin. The company announced the regulatory milestone after the market closed on Tuesday, with plans to launch the product in the upcoming summer, aligning with prior expectations.
The newly approved Stelo CGM stands out as it will be the first CGM available over the counter, a significant move for the product category. This accessibility, combined with a lower monthly cost than initially anticipated, is expected to enhance market penetration within the substantial new segment. DexCom estimates the potential market at approximately 25 million individuals in the United States who have Type 2 diabetes and do not take insulin.
Initially, Stelo will be offered as a cash-pay option while DexCom seeks to secure insurance coverage for the device. The company's sales forecast for 2024 includes an estimated $40 million from Stelo, and projections exceed $100 million in sales by 2025.
The Stelo system is designed based on DexCom's compact G7 sensor, tailored with specialized software for Type 2 diabetes patients who do not require insulin. Notably, the device will not feature the alerts or alarms typical of CGMs for insulin-dependent users and will offer an extended 15-day wear period, compared to the G7's current 10-day duration.
InvestingPro Insights
As DexCom, Inc. (NASDAQ:DXCM) gears up for the summer launch of its Stelo Continuous Glucose Monitoring system, the company's financial health and market valuation are key factors for investors to consider. According to real-time data from InvestingPro, DexCom's market capitalization stands at a robust $48.93 billion. The company's P/E ratio, a measure of its current share price relative to its per-share earnings, is high at 87.13, indicating that investors are willing to pay a premium for DexCom's growth potential.
The company's revenue growth is impressive, with a 24.49% increase over the last twelve months as of Q1 2023, and an even more significant quarterly growth rate of 26.9% for Q1 2023. This growth is a testament to DexCom's successful product portfolio and market strategy.
InvestingPro Tips highlight that DexCom's management has been actively buying back shares, signaling confidence in the company's future. Additionally, the company's cash flows can sufficiently cover interest payments, and its liquid assets exceed short-term obligations, indicating a solid financial position.
For those interested in deeper analysis and more InvestingPro Tips, there are 14 additional tips available on InvestingPro's platform for DexCom. Investors can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, which includes comprehensive insights into companies like DexCom.
It's worth noting that while analysts have revised their earnings downwards for the upcoming period, DexCom's strong revenue growth and market expansion strategies, such as the Stelo CGM launch, could potentially offset near-term earnings pressure. With the company's next earnings date slated for April 25, 2024, all eyes will be on DexCom's performance and strategic direction moving forward.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.